REMD Biotherapeutics, Inc. (“REMD Bio”), together with its subsidiary, Beijing CoSci-REMD Bio (“Cosci?REMD Bio”), today announced positive top-line results from a phase 2 clinical program of volagidemab (“Vola”) in patients with type 1 diabetes were presented at the American Diabetes Associations (ADA) 81st Scientific Sessions (ADA2021) as an oral presentation in the session entitled Novel Therapeutic Agents and Approaches.